Authors
Latest:
Turning the Tide on Opioid Prescribing PracticesIn 2017 there was a continued increase in opioid-related deaths in the United States, with more than 60,000 lives lost. Most opioid abusers report that their opioids are acquired with their own prescription or a prescription for someone else obtained illegally. Two recent retrospective studies found that in patients undergoing surgery for early non–small cell lung cancer, perioperative opioid use was associated with decreased OS and increased risk of recurrence.
Latest:
Cabazitaxel Advances Later-Line Treatment in Metastatic CRPC SettingDuring a Targeted Oncology Case-Based Roundtable event, A. Oliver Sartor, MD, discussed the results of cabazitaxel as a later-line treatment for patients with metastatic castration-resistant prostate cancer.
Latest:
Future of Myelofibrosis TreatmentsAaron Gerds, MD, MS, shares hopes that combination therapies now in trials, along with other novel approaches further down the pipeline like monoclonal antibodies, vaccines, and cellular therapies will likely radically advance treatment over the next 5 to 10 years.
Latest:
New Options Shape the Treatment Landscape of ALLAaron Logan, MD, PhD, discusses some of the treatment options available for patients with acute lymphoblastic leukemia.
Latest:
Dr. Aaron Spitz on the Role of Telemedicine in UrologyAaron Spitz, MD, talks about the emerging uses of telemedicine in urology. Telemedicine allows medical professionals to remotely diagnose and sometimes even treat patients through a variety of technology, including smartphones and tablet devices.
Latest:
Patient Selection for Imetelstat Benefits From Considering AEsAbdulraheem Yacoub, MD, discusses the adverse event profile of imetelstat when treating patients with myelodysplastic syndromes.
Latest:
Dr. Abraham Chachoua on Anti-PD-1 and Anti-PD-L1 Treatments in Lung CancerAbraham Chachoua, MD, associate professor of Oncology, NYU Langone Medical Center, talks about the present use of anti-PD-1 and anti-PD-L1 becoming the standard second-line treatment in lung cancer.
Latest:
Differentiating Between the Classes of Gastric CancerAdam Bass, MD, assistant professor of medicine, Dana-Farber Cancer Institute, discusses the differentiation between the classes of gastric cancer.
Latest:
Brufsky Recaps PALOMA-2 Study of Palbociclib in Black Patients with aBCAdam Brufsky, MD, PhD, FACP, discusses background and next steps of the phase 3 PALOMA-2 study which evaluated palbociclib plus letrozole in patients that identified as Black or Hispanic with advanced breast cancer.
Latest:
Gilteritinib Relapse Leads to Loss of FLT3-TKD Mutation in Patient With AMLAdam Fisch, MD, PhD, a clinical fellow in molecular genetic pathology at the Brigham’s Women’s Hospital, discusses the key points from a patient case he presented at the 2019 Association for Molecular Pathology Annual Meeting and Expo, in which the patient with acute myeloid leukemia harboring a FLT3-TKD mutation lost the mutation following relapse on gilteritinib.
Latest:
Functional Genomics of Barrett's Esophagus and Esophageal AdenocarcinomaAdam J. Bass, MD, assistant professor, Department of Medicine, Harvard Medical School, assistant professor of medicine, Division of Cellular and Molecular Oncology, Dana-Farber Cancer Institute, discusses functional genomics of Barrett's esophagus and esophageal adenocarcinoma.
Latest:
Dr. Adam Kibel on Treating Bone Metastases in Prostate CancerKibel cited both the STAMPEDE and CHAARTED trials, which showed the efficacy of docetaxel plus androgen deprivation therapy (ADT) in metastatic prostate cancer.
Latest:
Exploring Active Surveillance in Younger Patients With Prostate CancerAdam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.
Latest:
Immunotherapy Versus Targeted Therapy for Advanced MelanomaAdil Daud, MD, compares the roles of immunotherapy versus dabrafenib plus trametinib targeted therapy combinations in patients with advanced melanoma. The latter combination is appropriate and even preventative in select patients, but the decision between checkpoint immune therapy and immunotherapy comes down to what is best for each patient.
Latest:
Future of TROP2- and HER2-Directed ADCs in Breast CancerLaura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, provide closing thoughts on the evolving treatment landscape for HER-negative and HER2-low metastatic breast cancer.
Latest:
Curing Versus Managing CLLAdrian Wiestner, MD, PhD, senior investigator, National Institutes of Health, discusses curing or managing patients with chronic lymphocytic leukemia (CLL).
Latest:
Recent Advances in the Treatment Landscape of MelanomaAhmad Tarhini, MD, PhD, director of the Melanoma and Skin Cancer Program and Immune-Oncology Research at the Cleveland Clinic Taussig Cancer Institute, discusses 3 recent trials that are changing the adjuvant treatment landscape of melanoma. The treatments presented in these trials have less toxicities overall and less impact on the quality of life, according to Tarhini.
Latest:
Reviewing the Current Treatment Landscape for Patients With HCCAhmed Omar Kaseb, MD, discusses the current treatment landscape for patients with hepatocellular carcinoma.
Latest:
Later-Line Management of Metastatic Triple Negative Breast CancerTriple-negative breast cancer — defined as tumors that lack expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 amplification— is a heterogenous disease and clinically represents a major unmet need in the field of oncology. TNBC is associated with aggressive tumor biology and higher risk of recurrence and visceral metastasis, including brain metastasis.
Latest:
Checkpoint Inhibitors Under Investigation in Upper GI and Gastric CancersAiwu Ruth He, MD, discusses the current role of immune checkpoint inhibitors in upper gastrointestinal and gastric cancers and which patients are most likely to benefit from the anti–PD-1 agents.
Latest:
Challenge in Treating Patients With Multiple MyelomaAjai Chari, MD, discusses the biggest challenge in treating patients with multiple myeloma.
Latest:
The Future of Patient Care in RRMMDr Ajai Chari highlights the advantages of approved bispecific therapies as off-the-shelf options for patients with rapidly progressing multiple myeloma, highlighting the necessity for Phase 3 studies to confirm long-term benefits and safety. In closing, Dr Chari emphasizes the role of healthcare teams in managing side effects and complications, supporting the utility of bispecifics through unprecedented remissions and improved quality of life for patients.
